Key facts
- South Rampart Pharma’s last known valuation is $73.0M (Jan 2025).
- It has raised $9.1M; the latest was Later Stage VC ($3.2M) in Jan 2025.
- Notable investors include Gulf South Angels, Louisiana Economic Development, National Institutes of Neurological Disorders and Stroke, Ochsner Health, Ochsner Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for South Rampart Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for South Rampart Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About South Rampart Pharma
Developer of a clinical-stage biotech company designed to address the need for a safe and effective approach to relieving pain. The company develops synthesized and characterized new non-opioid and non-liver toxic molecules that activate pain signaling pathways in the midbrain's periaqueductal grey (PAG) region, enabling patients to overcome risks associated with current pain medicines, including lack of abuse as a non-opioid and no liver toxicity.
- Sector
- Healthcare
- HQ
- San Rafael, CA, United States
- Founded
- 2016
- Employees
- 4
- Website
- southrampartpharma.com/
- Ownership
- Privately Held (backing)
South Rampart Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in South Rampart Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on South Rampart Pharma in its N-PORT filings yet. We sweep new filings monthly.